Solventum Corporation · NYSE:SOLV
Solventum — Q1 2025 Earnings Presentation
13 slides from Solventum's earnings presentation, May 8, 2025
Slide 1: Q1 FY25 earnings presentation
Q1 FY25 earnings presentation May 8, 2025 © Solventum 2025. All rights reserved.
Slide 2: Forward-looking statements and use of document
Forward-looking statements and use of document This presentation and other materials Solventum has filed or will file with the U.S. Securities & Exchange Commission (“SEC”) (and oral communications that Solventum may make) contain or incorporate by reference statements that relate to future events a
Slide 3: Financial highlights
Financial highlights Q1 financial summary:1 • Net sales of $2.1B; +2.6%, organic sales growth +4.3% • Adjusted operating margins 19.7% • Adjusted EPS of $1.34 Updated FY25 guidance: • Increasing organic sales growth outlook by 50bps to +1.5% to +2.5% • Excludes additional SKU exit impact of 50bps •
Slide 4: Q1 FY25 Financial summary
Q1 FY25 Financial summary Dental Segment sales Key metrics Solutions MedSurg $328M non- (2.1%) Reported GAAP +0.4% Organic $1,157M +3.4% Reported GAAP2 +6.0% Organic Operating margin 7.3% 19.7% Health Total Solventum1 Information Systems EPS $0.78 $1.34 $329M $2,070M +3.6% Reported +2.6% Y/Y Reporte
Slide 5: MedSurg summary
MedSurg summary AWC $448M | 39% ++1.5% Y/Y Rep +2.8% Y/Y Org $1,157M +3.4% Y/Y Reported +6.0% Y/Y Organic Q1 financial results Q1 FY25 Q1 FY24 Y/Y IP&SS $710M | 61% Reported +3.4% Net sales $1,157M $1,119M Organic +6.0% +4.7% Y/Y Rep +8.2% Y/Y Org Tegaderm CHG Chlorhexidine Gluconate IV Securement D
Slide 6: Dental Solutions summary
Dental Solutions summary Q1 financial results Q1 FY25 Q1 FY24 Y/Y Reported (2.1)% Net sales $328M $335M Organic +0.4% 3M Filtek Easy Match Universal Restorative a simplified shading system designed to streamline Segment drivers: single-shade restorations from the start – all while providing the flex
Slide 7: Health Information Systems summary
Health Information Systems summary Q1 financial results Q1 FY25 Q1 FY24 Y/Y Reported +3.6% Net sales $329M $317M Organic +3.9% Segment drivers: 3M 360 Encompass System latest generation coding solution combines coding • Organic growth driven by continued adoption of 360 Encompass Revenue Cycle and r
Slide 8: Purification & Filtration summary
Purification & Filtration summary Q1 financial results Q1 FY25 Q1 FY24 Y/Y Reported (0.9)% Net sales $242M $245M Organic +2.2% Harvest RC Centrate Chromatographic Clarifier improves biopharmaceutical manufacturing product Segment drivers: yields with differentiated technology that enables faster spe
Slide 9: FY2025 financial guidance and considerations
FY2025 financial guidance and considerations Additional considerations: Organic sales growth +1.5% to +2.5% • FX Impact: Increase +50bps vs initial guide +2.0% to +3.0% excluding ‒ Neutral impact to reported sales growth vs. ~50bps of SKU-exit impact prior assumption of ~150bps headwind • Incrementa
Slide 10: Appendix
Appendix © Solventum 2025. All rights reserved. 10
Slide 11: Non-GAAP financial measures
Non-GAAP financial measures In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adj
Slide 12: Q1 FY25 detailed non-GAAP reconciliation and free cash flow
Q1 FY25 detailed non-GAAP reconciliation and free cash flow Spin-off & Sale of Purification (Millions, except per share separation-related Certain litigation- and Filtration- Q1 FY24 data) Q1 FY25 GAAP Amortization Restructuring costs related costs related non-GAAP Net sales 2,070 2,070 Gross margin
Slide 13: Glossary and definitions
Glossary and definitions Abbreviation Elaboration Organic sales growth Total net sales less the impacts of foreign currency and sales from business AWC Advanced Wound Care acquisitions or divestitures for the first 12 months post-transaction FCF Free cash flow Adjusted operating income Operating inc